Dr Singer on Systemic Pembrolizumab Monotherapy in BCG-unres

Eric A. Singer, MD, discusses the use of systemic pembrolizumab monotherapy in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle invasive bladder cancer.

Related Keywords

, Ohio State University Comprehensive Cancer Center , Division Of Urologic Oncology , Ohio State University Wexner Medical Center , Urologic Oncology , Bacillus Calmette Gu , Pembrolizumab Monotherapy , Erica Singer , D , Bacillus Calmette Guérin Bcg Unresponsive , High Risk Non Muscle Invasive Bladder Cancer ,